The biotech submitted a highly anticipated regulatory filing.
News & Analysis: Biogen
The market is cheering progress for the company's Alzheimer's disease candidate.
The Nasdaq once again led the way for the broader stock market.
Which of these two drugmakers will outperform the other on the stock market moving forward?
A patent ruling involving Biogen’s blockbuster drug weighed on share performance.
Biogen is more profitable, more innovative, and its stock may be undervalued to boot.
Demand for Alzheimer's medication is expected to grow as the population of older adults rises.
Which stock wins in a matchup between these two coronavirus-focused biotechs?
Investors should be careful not to rely too heavily on valuation multiples.
A patent appeal and a regulatory decision may produce huge rewards -- or losses.